content_image/63966.jpg
<img src='content_image/63966.jpg'>

agreement, 3) $4.5 million loss on the permanent impairment of equity investments, 4) $2.0 million gain on the sale of divested pharmaceutical products in Brazil, 5) $4.2 million unrealized gain on derivative instruments, and 6) $4.4 million associated with the 2002 spin-off of the Company’s ophthalmic surgical and contact lens care businesses. 

The adjusted amounts in 2000 exclude the after-tax effects of the following: 1) a $0.2 million restructuring charge, 2) $1.3 million gain on the sale of investments, and 3) $2.0 million in expenses from partnering agreements. 

The adjusted amounts in 1999 exclude the after-tax effects of the following: 1) $3.6 million in restructuring charge reversals, 2) $0.8 million in asset gains, reducing write-offs recorded in 1998, 3) $14.0 million gain on sales of investments, 4) $6.9 million contribution to The 

Allergan Foundation, 5) $3.8 million of income, net of expenses of $5.7 million, from partnering agreements, and 6) $1.1 million in certain one-time costs. 

(b)Diluted earnings per share adjusted by $0.04 for the first six months of 2002 and by $0.07 for the full year 2001 to reflect dissynergies related to the spin-off of Advanced Medical Optics. 

The foregoing presentation contains certain non-GAAP financial measures, including con- stant currency growth rates, and non-GAAP and pro forma adjustments. For a reconciliation of these non-GAAP financial measures to comparable GAAP financial measures, please refer to pages 6 and 7 of this Annual Report. 

